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BACKGROUND: The function of high- density lipoprotein can change from protective to proatherosclerotic under inflammatory 
conditions. Herein, we studied whether inflammation could modify the relationship between high- density lipoprotein level and 
risk of adverse outcomes in patients with chronic kidney disease .
METHODS AND RESULTS: In total, 1864 patients from the prospective KNOW- CKD (Korean Cohort Study for Outcome in 
Patients With Chronic Kidney Disease) were enrolled. The main predictor was high- density lipoprotein cholesterol (HDL- C) 
level. Presence of inflammation was defined by hs- CRP (high- sensitivity C- reactive protein) level of ≥1.0 mg/L. The primary 
outcome was extended major adverse cardiovascular events. During 9231.2 person- years of follow- up, overall incidence of 
the primary outcome was 15.8 per 1000 person- years. In multivariable Cox analysis after adjusting for confounders, HDL- C 
level was not associated with the primary outcome. There was a significant interaction between the inflammatory status and 
HDL- C for risk of extended major adverse cardiovascular events (P=0.003). In patients without inflammation, the hazard ratios 
(HRs) (95% CIs) for HDL- C levels <40, 50 to 59, and ≥60 mg/dL were 1.10 (0.50– 1.82), 0.95 (0.50– 1.82), and 0.42 (0.19– 0.95), 
respectively, compared with HDL- C of 40 to 49 mg/dL. However, the significant association for HDL- C ≥60 mg/dL was not 
seen after Bonferroni correction. In patients with inflammation, we observed a trend toward increased risk of extended major 
adverse cardiovascular events in higher HDL- C groups (HRs [95% CIs], 0.73 [0.37– 1.43], 1.24 [0.59– 2.61], and 1.56 [0.71– 3.45], 
respectively), but without statistical significance.
CONCLUSIONS: The association between HDL- C level and adverse cardiovascular outcomes showed reverse trends based on 
inflammation status in Korean patients with chronic kidney disease.
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Cardiovascular disease (CVD) is the leading cause of mortality worldwide. Besides the traditional risk factors, such as hypertension, diabetes mellitus, 
and hypercholesterolemia, chronic kidney disease 
(CKD) is considered as a nontraditional risk factor 
for CVD. The risk of adverse atherosclerotic vascu-
lar events increases, even in patients with mildly de-
creased kidney function.1 Notably, other nontraditional 
risk factors, such as inflammation, oxidative stress, and 
CKD- related bone and mineral disorders, are highly 
prevalent among patients with CKD. These factors can 
collectively lead to remarkably high mortality rates.
Among the traditional risk factors, dyslipidemia, 
which is characterized by the elevated levels of tri-
glycerides and low- density lipoprotein (LDL) choles-
terol and decreased levels of high- density lipoprotein 
cholesterol (HDL- C), is commonly encountered in pa-
tients with CKD. The role of LDL as a major culprit in 
the development of atherosclerosis has been well es-
tablished. The lowering of LDL cholesterol levels re-
duces the occurrence of major adverse cardiovascular 
events (MACEs). The beneficial effects of LDL choles-
terol lowering therapy have been shown in nondialysis 
patients with CKD.2 In contrast, high- density lipopro-
tein (HDL), known as the “good cholesterol,” provides 
antiatherogenic effects mostly attributed to its potent 
anti- inflammatory, antioxidative, and antithrombotic 
properties. It also plays a role in reverse cholesterol 
transport,3 through which surplus cholesterol is re-
moved from lipid- laden macrophages and peripheral 
tissues, thereby providing atheroprotection. An in-
verse linear relationship has been established between 
HDL- C level and CVD risk.4
In contrast to the traditional concept of HDL- C, re-
cent Mendelian studies showed no causality between 
HDL- C and CVD.5,6 In addition, several randomized 
controlled studies failed to demonstrate the bene-
ficial effects of HDL- C on the prevention of CVD.7,8 
Moreover, there has been evidence suggesting con-
trasting effects of HDL in certain conditions, such as 
diabetes mellitus and/or CKD, wherein HDL can in-
duce endothelial dysfunction and arterial hypertension 
through the generation of systemic oxidative stress 
rather than conferring vascular protection.9 In addition, 
there is growing evidence that the composition of HDL, 
rather than the circulating HDL- C level, determines its 
functional properties.10 In contrast to the conventional 
notion about the inverse linear relationship between 
the HDL- C levels and adverse outcomes, a U- shaped 
association of HDL- C levels with mortality has been re-
ported in a large population- based study.11 Therefore, 
the discrepancy in the clinical implications of HDL 
under various conditions should be clarified.
It is well established that inflammation greatly 
contributes to the pathogenesis of atherosclerosis. 
Low- grade inflammation is a key feature of CKD, and 
persistent inflammation can accelerate the decline in 
kidney function and worsen vascular disease in pa-
tients with CKD.12 The functional properties of HDL 
can be influenced by inflammation,10 and its antioxida-
tive and antithrombotic actions become less effective 
during kidney failure.13,14 Therefore, we hypothesized 
that inflammation can alter the conventional relation-
ship between the HDL- C level and CVD risk in patients 
with CKD. In this study, we examined the clinical im-
plications of HDL- C levels for predicting MACEs in the 
presence and absence of inflammation among Korean 
patients with CKD.
METHODS
Because of ethical issues and data protection regu-
lations, data that support the findings of the present 
study cannot be made publicly available.
CLINICAL PERSPECTIVE
What Is New?
• In this Korean cohort study including 1864 pa-
tients with chronic kidney disease, there was a 
significant interaction between the inflammatory 
status and high- density lipoprotein cholesterol 
for risk of cardiovascular outcomes.
• In patients without inflammation, a higher 
high- density lipoprotein cholesterol level was 
nonlinearly associated with a lower risk of cardi-
ovascular outcomes, although this association 
was not significant after statistical adjustment 
with Bonferroni correction.
• In contrast, the opposite graded association 
was observed in patients with inflammation.
What Are the Clinical Implications?
• In patients with chronic kidney disease, clinical 
implications of high- density lipoprotein choles-
terol level can be differently interpreted on the 
basis of the inflammatory status.
Nonstandard Abbreviations and Acronyms
eMACE extended major adverse cardiovascular 
event
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Study Design and Participants
The KNOW- CKD (Korean Cohort Study for Outcome in 
Patients With Chronic Kidney Disease) is a nationwide 
multicenter prospective study aimed at investigating 
renal and cardiovascular outcomes in Korean patients 
with predialysis CKD, stages 1 through 5. The detailed 
design, methods, study rationale, participant enroll-
ment, and protocol summary have been described 
previously (NCT01630486 at http://www.clini caltr 
ials.gov).15 In total, 2238 adults, aged 20 to 75 years, 
were enrolled from 9 tertiary- care hospitals between 
2011 and 2016. Among the participants, 58 patients 
who were lost to follow- up after baseline visit were 
excluded. In addition, 316 patients with missing data 
on demographics, including body mass index, socio-
economic status based on income, and educational 
background; behavioral patterns, including history of 
smoking; laboratory test results, including fasting blood 
glucose, serum albumin, phosphate, and HDL- C levels; 
and baseline renal functions, including glomerular fil-
tration rate and urine protein/creatinine ratio, were ex-
cluded. Finally, 1864 participants were included in the 
analysis (Figure S1). Detailed description on data col-
lection is in Data S1. We used the creatinine method, 
which requires calibration traceable to isotope dilu-
tion mass spectrometry, and calculated the estimated 
glomerular filtration rate using the CKD Epidemiologic 
Collaboration equation.16 Urine protein/creatinine ratio 
was calculated as the urine protein concentration di-
vided by the urine creatinine concentration (g/g).
This study was conducted in accordance with 
the principles of Declaration of Helsinki, and the 
study protocol was approved by the institutional re-
view board at each participating clinical center, 
as follows: Yonsei University Severance Hospital 
(4- 2011- 0163), Seoul National University Hospital 
(1104- 089- 359), Seoul National University Bundang 
Hospital (B- 1106/129- 008), Kangbuk Samsung 
Medical Center (2011- 01- 076), Seoul St. Mary’s 
Hospital (KC11OIMI0441), Gil Hospital (GIRBA2553), 
Eulji General Hospital (201105- 01), Chonnam National 
University Hospital (CNUH- 2011- 092), and Pusan Paik 
Hospital (11- 091) in 2011. All participants provided the 
written informed consent.
Exposure and Outcome Ascertainment
The exposures of interest were serum HDL- C level 
and presence of inflammation, which was defined 
as hs- CRP (high- sensitivity C- reactive protein) level 
≥1.0 mg/L, following the recommendations proposed 
by the Centers for Disease Control and Prevention 
and the American Heart Association.17 Considering a 
possible nonlinear relationship with the outcomes, the 
serum HDL- C levels were categorized into the follow-
ing 4 groups with 10- mg/dL increments: <40, 40 to 49 
(reference), 50 to 59, and ≥60 mg/dL. The primary out-
come was extended MACEs (eMACEs), including fatal 
and nonfatal cardiovascular events, such as myocar-
dial infarction, unstable angina, coronary intervention/
surgery, hospitalization for heart failure, symptomatic 
arrhythmia, and/or cardiac death. Secondary end 
points included separate outcomes of nonfatal MACEs 
and all- cause mortality. Participants were followed up 
until March 31, 2019, and were censored at the date of 
the last visit or the occurrence of events, as applicable.
Statistical Analysis
Data from descriptive analyses are presented as 
mean±SD, median (interquartile range), or propor-
tion, as appropriate. Data were compared using the 
Student t test, analysis of variance, Kruskal- Wallis test, 
and χ2 test. Cox proportional- hazards model was used 
to evaluate the associations between serum HDL- C 
category and subsequent cardiovascular outcomes 
based on the presence of inflammation. This associa-
tion was assessed with HDL- C being treated as a con-
tinuous variable per SD increase. On the basis of the 
confounding factors, 3 models were constructed for 
each analysis. Factors that were included in a stepwise 
manner for adjustment included the following: fac-
tors known to affect the risk of CVD, factors that sig-
nificantly differed among 4 HDL- C groups, and factors 
shown to have significant association with the primary 
outcome (ie, P<0.10) in the unadjusted model. Model 
1 was adjusted for sociodemographic factors and an-
thropometric data, including age, sex, smoking status, 
socioeconomic status, educational level, body mass 
index, systolic blood pressure, presence of coronary 
artery disease, and diabetes mellitus. Model 2 was 
adjusted for the laboratory parameters, including esti-
mated glomerular filtration rate, urine protein/creatinine 
ratio, levels of fasting blood glucose, LDL cholesterol, 
triglyceride, serum albumin, and hs- CRP, in addition to 
variables adjusted in model 1. Model 3 was further ad-
justed for medication use, including renin- angiotensin 
system blockers, diuretics, and lipid- lowering drugs 
(statins). We further performed multiple comparisons 
among HDL categories after statistical adjustment 
using Bonferroni method. For sensitivity analyses to 
assess robustness of our findings, study participants 
were stratified into quartiles according to the serum 
levels of HDL- C. In addition, another different cutoff 
value for the status of inflammation was examined 
using the median value of hs- CRP. Furthermore, we 
constructed the time- varying model with lipid- lowering 
drugs treated as time- varying covariate. For second-
ary analyses for nonfatal MACEs, we used a cause- 
specific hazard function for competing risk model. In 
this analysis, noncardiac death that occurred before 
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was censored. Kaplan- Meier curve analysis for the 
cumulative incidence of primary outcome was used 
to derive the incidence rates, and differences among 
groups were compared by log- rank test. We explored 
the continuous and nonlinear relationship between 
serum HDL- C level and study outcomes using fully 
adjusted restricted cubic spline model with 3 knots 
placed at the 25th, 50th, and 75th percentiles. To ex-
amine the effect modification of the relationship be-
tween HDL- C level and inflammation, we performed 
subgroup analyses stratified by age (<60 versus 
≥60 years), sex, body mass index (<25 versus ≥25 kg/
m2), medical history of diabetes mellitus (presence 
versus absence), systolic blood pressure (<140 versus 
≥140 mm Hg), serum albumin (<4.0 versus ≥4.0 g/dL), 
baseline estimated glomerular filtration rate (<50 ver-
sus ≥50 mL/min per 1.73 m2), and urine protein/cre-
atinine ratio (<1.0 versus ≥1.0 g/g). All exposure- event 
associations are expressed as hazard ratios (HRs) and 
95% CIs. The differences with P<0.05 were considered 
statistically significant. All statistical analyses were per-
formed using Stata, version 14.2 (StataCorp, College 
Station, TX), and R, version 3.4.3 (www.r- proje ct.org; R 
Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Baseline Characteristics of the 
Participants
The baseline characteristics of the participants, strati-
fied by the HDL- C categories, are presented in Table 1 
and Table S1. The mean HDL- C level was 33.6±4.6 mg/
dL. The histogram and kernel density plot, showing the 
distribution of HDL- C, are presented in Figure S2. Most 
of the patients with higher HDL- C levels were women, 
young, and nonsmokers, had lower body mass index, 
and had fewer comorbid conditions, such as hyperten-
sion, diabetes mellitus, coronary artery disease, and 
cerebrovascular disease. These patients had lower hs- 
CRP and fasting blood glucose levels, more preserved 
kidney function, and decreased urinary protein excre-
tion. A significant inverse relationship between the 
HDL- C and hs- CRP levels (γ=−0.234; P<0.001) was 
observed (Figure S3).
Association of HDL- C Level With the Risk 
of eMACEs
During 9231.2  person- years of follow- up (median, 
5.1 years), the primary outcome of eMACEs was ob-
served in 140 (7.5%) patients with an incidence rate 
of 15.8 per 1000 person- years. There were 44 (8.6%), 
44 (8.2%), 31 (7.6%), and 21 (5.2%) primary outcome 
events in patients with HDL- C levels of <40, 40 to 49, 
50 to 59, and ≥60  mg/dL, respectively (Table  2). In 
multivariable Cox model after sequential adjustments, 
no association of HDL- C level with the risk of eMACEs 
was observed (Table 3 and Figure 1). Compared with 
the HDL- C category of 40 to 49  mg/dL, the HDL- C 
categories of <40, 50 to 59, and ≥60 mg/dL showed 
adjusted HRs (95% CIs) of 0.93 (0.59– 1.44), 1.05 (0.65– 
1.68), and 0.72 (0.41– 1.24), respectively. In the addi-
tional analysis with HDL- C as a continuous variable, 
1- SD increase in HDL- C level was not associated with 
the primary outcome.
Risk- Modifying Effect of Inflammation on 
the Relationship Between HDL- C Level 
and Cardiovascular Outcome
We examined whether the association between the 
HDL- C level and risk of eMACEs differed according 
to the inflammatory status. There was a significant 
interaction between the inflammatory status and 
HDL- C for risk of eMACEs (P=0.003). Among the pa-
tients without inflammation (hs- CRP <1.0 mg/L), the 
incidence rate of eMACEs decreased gradually in pa-
tients with increasing HDL- C concentrations. A non-
linear inverse relationship was observed between the 
HDL- C level and risk of eMACEs in multivariable Cox 
analysis. Adjusted HRs (95% CIs) for the HDL- C cat-
egories of <40, 50 to 59, and ≥60 mg/dL were 1.10 
(0.60– 2.00), 0.95 (0.50– 1.82), and 0.42 (0.19– 0.95), 
respectively, compared with the HDL- C category of 
40 to 49 mg/dL (Table 3 and Figure 1). However, this 
association was not significant after statistical adjust-
ment with Bonferroni correction (Table S2). Additional 
analysis with HDL- C as a continuous variable showed 
that 1- SD increase in the HDL- C level was significantly 
associated with a 33% lower risk of eMACEs in pa-
tients without inflammation (Table 3). In contrast, this 
relationship disappeared among patients with inflam-
mation (hs- CRP ≥1.0 mg/L). Multivariable Cox models 
revealed a graded increase in the HRs for the risk of 
eMACEs, but these did not reach statistical signifi-
cance. Adjusted HRs (95% CIs) for the HDL- C cate-
gories of <40, 50 to 59, and ≥60  mg/dL were 0.73 
(0.37– 1.43), 1.24 (0.59– 2.61), and 1.56 (0.71– 3.45), 
respectively, compared with the HDL- C category of 
40 to 49  mg/dL (Table  3 and Figure  1). The oppo-
site direction of the association between HDL- C and 
eMACEs in patients with inflammation was also ob-
served when HDL- C was treated as a continuous vari-
able (Table 3). As shown in Figure 2, the unadjusted 
cumulative incidence of the primary outcome was no-
tably lower in patients without inflammation and with 
HDL- C levels of ≥60 mg/dL, whereas this pattern dis-
appeared in those with inflammation. Restricted cubic 
spline curves for the adjusted HRs for eMACEs also 
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Table 1. Baseline Characteristics of Participants Based on HDL- C Categories
Characteristics
HDL- C Categories, mg/dL
Total (N=1864) P Value
<40   
(N=514)
40– 49   
(N=537)





Age, y 56.2±11.3 53.6±12.1 52.6±12.7 51.2±12.7 53.6±12.3 <0.001
Men, n (%) 405 (78.8) 354 (65.9) 222 (54.5) 152 (37.4) 1133 (60.8) <0.001
BMI, kg/m2 25.29±3.12 25.02±3.24 24.38±3.51 23.16±3.34 24.55±3.39 <0.001
SBP, mm Hg 128.5±16.9 127.9±14.7 127.1±16.7 126.5±15.3 127.58±15.9 0.22
DBP, mm Hg 76.2±11.2 76.8±10.4 77.7±11.7 77.1±11.0 76.9±11. 0.25
Economic status, n (%) 0.02
≥$4905/mo 95 (18.5) 135 (25.1) 94 (23.1) 111 (27.3) 435 (23.3)
$1635– $4905/mo 282 (54.9) 277 (51.6) 218 (53.6) 218 (53.7) 995 (53.4)
<$1635/mo 137 (26.7) 125 (23.3) 95 (23.3) 77 (19.0) 434 (23.3)
Education, n (%) 0.39
<9 y 69 (13.4) 64 (11.9) 56 (13.8) 40 (9.9) 229 (12.3)
9– 12 y 69 (13.4) 66 (12.3) 44 (10.8) 44 (10.8) 223 (12.0)
≥12 y 376 (73.2) 407 (75.8) 307 (75.4) 322 (79.3) 1412 (75.8)
Smoking status, n (%) <0.001
Never 192 (37.4) 282 (52.5) 236 (58.0) 290 (71.4) 1000 (53.6)
Current 113 (22.0) 93 (17.3) 60 (14.7) 34 (8.4) 300 (16.1)
Former 209 (40.7) 162 (30.2) 111 (27.3) 82 (20.2) 564 (30.3)
Comorbidities
Hypertension, n (%) 509 (99.0) 525 (97.8) 389 (95.6) 369 (90.9) 1792 (96.1) <0.001
Diabetes mellitus, n (%) 231 (44.9) 200 (37.2) 97 (23.8) 94 (23.2) 622 (33.4) <0.001
MI, n (%) 20 (3.9) 8 (1.5) 1 (0.2) 1 (0.2) 30 (1.6) <0.001
CVD, n (%) 40 (7.8) 31 (5.8) 29 (7.1) 11 (2.7) 111 (6.0) 0.008
Charlson comorbidity index 4.1±2.1 3.5±2.1 3.0±2.3 2.7±2.1 3.4±2.2 <0.001
Medication, n (%) 226 (36.8) 173 (27.3) 73 (15.9) 87 (16.4) 559 (25.0)
ACE inhibitor 52 (10.1) 69 (12.8) 39 (9.6) 43 (10.6) 203 (10.9) 0.36
ARB 431 (83.9) 434 (80.8) 323 (79.4) 303 (74.6) 1491 (80.0) 0.006
Diuretics 210 (40.9) 189 (35.2) 104 (25.6) 79 (19.5) 582 (31.2) <0.001
Statin 0.04
No statin 229 (44.6) 257 (47.9) 199 (48.9) 209 (51.5) 894 (48.0)
Low intensity 39 (7.6) 58 (10.8) 21 (5.2) 26 (6.4) 144 (7.7)
Moderate intensity 235 (45.7) 208 (38.7) 177 (43.8) 160 (39.4) 780 (41.8)
High intensity 11 (2.1) 14 (2.6) 10 (2.5) 11 (2.7) 46 (2.5)
Niacin 0 (0.0) 3 (0.6) 0 (0.0) 0 (0.0) 3 (0.2) 0.06
Laboratory parameters
eGFR, mL/min per 1.73 m2 41.4±24.9 52.6±30.0 57.9±31.1 64.2±33.3 53.3±30.9 <0.001
BUN, mg/dL 32.5±17.0 28.1±15.1 26.4±15.2 24.6±14.4 28.2±15.8 <0.001
Albumin, g/dL 4.1±0.4 4.2±0.4 4.2±0.4 4.2±0.4 4.2±0.4 0.07
Fasting glucose, mg/dL 114.3±42.5 112.8±40.8 108.2±37.2 103.5±30.4 110.2±38.7 <0.001
hs- CRP, mg/L 0.9 (0.4– 2.3) 0.7 (0.3– 1.7) 0.5 (0.2– 1.5) 0.3 (0.1– 1.0) 0.6 (0.2– 1.64) <0.001
Tchol, mg/dL 158.3±37.0 173.1±37.8 177.9±36.0 191.0±37.2 173.9±38.7 <0.001
HDL- C, mg/dL 33.6±4.6 44.3±2.8 54.2±3.0 72.1±13.0 49.6±15.5 <0.001
Triglyceride, mg/dL 176.0 (130.0– 244.0) 141.5 (101.0– 197.0) 112.0 (85.0– 161.0) 95.0 (73.0– 135.5) 132.0 (92.0– 192.0) <0.001
LDL- C, mg/dL 88.6±29.7 100.3±32.2 100.2±30.6 100.0±31.7 96.9±31.5 <0.001
uPCR, g/g 0.6 (0.2– 1.8) 0.5 (0.2– 1.5) 0.4 (0.1– 1.3) 0.4 (0.1– 1.4) 0.5 (0.1– 1.5) 0.002
Data are presented as mean±SD, number (percentage), or median (interquartile range). ACE indicates angiotensin- converting enzyme; ARB, angiotensin II 
receptor blocker; BMI, body mass index; BUN, blood urea nitrogen; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular 
filtration rate; HDL- C, high- density lipoprotein cholesterol; hs- CRP, high- sensitivity C- reactive protein; LDL- C, low- density lipoprotein cholesterol; MI, myocardial 
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sensitivity analyses with HDL- C quartiles (Table  S3) 
and with the different cutoff of hs- CRP (Table S4) all 
showed that the different association of HDL- C with 
eMACEs by the inflammatory status remained consist-
ent. Furthermore, in a time- varying model to account 
for time- dependent effects of statins on outcomes, 
such a bidirectional association persisted (Table S5).
Secondary Outcome Analysis
Nonfatal MACEs occurred in 122 (6.5%) patients; the 
incidence rate was lower in patients with higher HDL- C 
levels (Table 2). In line with the results of primary out-
come analysis, the relationship between the HDL- C 
level and nonfatal MACEs varied significantly, depend-
ing on the inflammatory status. Overall, the HDL- C level 




<40 mg/dL 40– 49 mg/dL 50– 59 mg/dL ≥60 mg/dL
All
No. of participants 1864 514 537 407 406
Person- years 8888.3 2323.6 2549.8 1922.2 2092.7
eMACE*
Events, n (%) 140 (7.5) 44 (8.6) 44 (8.2) 31 (7.6) 21 (5.2)
Incidence rate per 1000 person- years 15.8 18.9 17.3 16.1 10.0
Non- fatal MACE
Events, n (%) 122 (6.5) 39 (7.6) 37 (6.9) 28 (6.9) 18 (4.4)
Incidence rate per 1000 person- years 13.7 16.8 14.5 14.6 8.6
All- cause mortality
Events, n (%) 96 (5.2) 37 (7.2) 25 (4.7) 19 (4.7) 15 (3.7)
Incidence rate per 1000 person- years 10.4 15.1 9.5 9.5 7.0
In the absence of inflammation
No. of participants 1142 260 314 267 301
Person- years 5495.5 1141.9 1473.1 1291.2 1589.4
eMACE
Events, n (%) 76 (6.7) 24 (9.2) 25 (8.0) 18 (6.7) 9 (3.0)
Incidence rate per 1000 person- years 13.8 21.0 17.0 13.9 5.7
Non- fatal MACE
Events, n (%) 67 (5.9) 21 (8.1) 22 (7.0) 16 (6.0) 8 (2.7)
Incidence rate per 1000 person- years 12.2 18.4 14.9 12.4 5.0
All- cause mortality
Events, n (%) 45 (3.9) 18 (6.9) 11 (3.5) 9 (3.4) 7 (2.3)
Incidence rate per 1000 person- years 7.9 14.9 7.3 6.7 4.3
In the presence of inflammation
No. of participants 722 254 223 140 105
Person- years 3392.8 1181.7 1076.7 631.0 503.3
eMACE
Events, n (%) 64 (8.9) 20 (7.9) 19 (8.5) 13 (9.3) 12 (11.4)
Incidence rate per 1000 person- years 18.9 16.9 17.6 20.6 23.8
Non- fatal MACE
Events, n (%) 55 (7.6) 18 (7.1) 15 (6.7) 12 (8.6) 10 (9.5)
Incidence rate per 1000 person- years 16.2 15.2 13.9 19.0 19.9
All- cause mortality
Events, n (%) 51 (7.1) 19 (7.5) 14 (6.3) 10 (7.1) 8 (7.6)
Incidence rate per 1000 person- years 14.3 15.2 12.6 15.1 14.8
eMACE indicates extended major adverse cardiovascular events; and HDL- C, high- density lipoprotein cholesterol.
*eMACE included both fatal and non- fatal major cardiovascular events, such as myocardial infarction, unstable angina, coronary intervention/surgery, 
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was not associated with the risk of nonfatal MACEs. 
However, an inverse association was observed for this 
outcome among patients without inflammation; in par-
ticular, the HDL- C level of ≥60 mg/dL was associated 
with a 59% (95% CI, 0.17– 0.97) lower risk of nonfa-
tal MACEs than the HDL- C level of 40 to 49  mg/dL. 
Notably, this association was reversed in patients with 
inflammation, but the difference was not statistically 
significant (Table S6 and Figure S5).
No significant difference was observed in the risk 
of all- cause death among the patients stratified by 
HDL- C categories (Table S7 and Figure S6). In a sep-
arate analysis based on the inflammatory status, the 
adjusted HRs were lower in patients without inflamma-
tion and with higher HDL- C level compared with the 
reference group of HDL- C 40 to 49 mg/dL; however, 
the results were not statistically significant. The cumu-
lative incidence curves for nonfatal MACEs (Figure S7) 
and all- cause death (Figure S8) yielded similar findings.
Subgroup Analysis
We tested the effect modification on the relationship 
between HDL- C level and inflammation for eMACEs 
in the prespecified subgroups (Figure S9). Overall, the 
risk- modifying effect of inflammation on the relation-
ship between HDL- C level and the risk of eMACEs 
existed among most subgroups. However, significant 
interaction was observed between serum albumin and 
HDL- C levels for the primary outcome based on the in-
flammatory status. In patients with serum albumin level 
<4.0 g/dL, the adjusted HR per SD increase in HDL- C 
was 0.32 (95% CI, 0.10– 1.00) in the absence of inflam-
mation, whereas it was 2.38 (95% CI, 1.19– 4.77) in the 
presence of inflammation.
DISCUSSION
In the present study, we showed that the relationship 
of HDL- C level with CVD differed depending on the 
inflammatory status in patients with CKD. There was 
a significant interaction between inflammation and 
HDL- C level for the primary outcome. In the absence of 
inflammation, HDL- C level ≥60 mg/dL was associated 
with a lower risk of eMACEs, although statistical signifi-
cance was lost after Bonferroni correction. In contrast, 
Figure 1. Association of high- density lipoprotein 
cholesterol (HDL- C) level with the primary outcome.
In multivariable Cox model after sequential adjustments, 
the relationship of HDL- C level with cardiovascular diseases 
differed depending on the inflammatory status in patients with 
chronic kidney disease. In the absence of inflammation, HDL- C 
level ≥60 mg/dL was associated with a lower risk of extended 
major adverse cardiovascular events (eMACEs), whereas this 
relationship was reversed in the presence of inflammation. 
The model is adjusted for age, sex, body mass index, smoking 
status, socioeconomic status, educational status, systolic blood 
pressure, presence of coronary artery disease, diabetes mellitus, 
laboratory parameters, including fasting blood glucose, low- 
density lipoprotein cholesterol, triglycerides, serum albumin, hs- 
CRP (high- sensitivity C- reactive protein), estimated glomerular 
filtration rate, and urine protein/creatinine ratio, and medications’ 
use, including renin- angiotensin system blockers, diuretics, and 
statins. Bars represent 95% CIs. HR indicates hazard ratio.
Figure 2. Kaplan- Meier curves for the cumulative incidence of the primary outcome based on the high- density lipoprotein 
cholesterol (HDL- C) categories.
A, Regardless of inflammation. B, In the absence of inflammation. C, In the presence of inflammation. The cumulative incidence of 
extended major adverse cardiovascular events was notably lower in patients without inflammation and with HDL- C level ≥60 mg/dL, 
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the opposite trend was observed for the association 
between HDL- C and adverse CVD in the presence of 
inflammation. We showed a similar relationship using 
various analytical models. The difference in the na-
ture of HDL- C based on inflammation was particularly 
evident for nonfatal cardiovascular events and more 
pronounced in patients with lower albumin levels. Our 
findings suggest that inflammation modifies the rela-
tionship between HDL- C level and the risk of eMACEs, 
and the beneficial association of high HDL- C levels is 
lost under the influence of inflammation in patients with 
CKD.
The notion of HDL- C being a “good cholesterol” 
was questioned in recent studies that reported 
nonlinear associations between the HDL- C con-
centrations and mortality.18,19 A recent cohort study 
reported a U- shaped relationship between the 
HDL- C level and mortality.11 In addition to Mendelian 
randomization studies that failed to find the causal 
genetic association of HDL- C with CVD,5,6 some 
genetic variants associated with higher HDL- C con-
centrations have been reported to have paradoxi-
cally increased the CVD risk.20,21 Herein, we sought 
to examine if such discrepancy in the clinical impli-
cations of HDL- C might be attributed to inflamma-
tion. Our findings suggest that inflammation had a 
risk- modifying effect on the relationship between the 
HDL- C level and adverse outcomes in patients with 
CKD.
We particularly focused on inflammation because 
inflammatory responses affect metabolism and com-
position of HDL,22 thereby suggesting a possible link 
between altered HDL function and inflammation under 
noxious medical conditions. This was suggested in 
previous studies, which indicated the loss of benefi-
cial effects of HDL- C in patients with diabetes mellitus 
and coronary artery disease, who generally present 
with increased inflammation.23,24 CKD is also a con-
dition wherein HDL- mediated vasoprotective effects 
are significantly impaired.9 As patients with CKD 
are burdened with uremia, inflammation, and oxida-
tive stress,25,26 HDL may impart the pro- oxidant and 
proinflammatory effects in the setting of renal failure. 
Consistent with previous investigations that analyzed 
the inflammation- related association between elevated 
HDL- C and the cardiovascular risk in nondiabetic post-
infarction patients and a male population- based co-
hort,27,28 we showed that higher HDL concentrations 
were associated with a lower risk for eMACEs and non-
fatal MACEs in the absence of inflammation, whereas 
opposite association was observed in the presence of 
inflammation. These findings were supported by sub-
group analysis. Notably, the risk- modifying effect of in-
flammation was observed in patients with lower serum 
albumin level. Albumin is a negative acute- phase re-
actant; its concentration represents the nutritional 
status and is inversely correlated with inflammation. In 
the present study, a beneficial association of higher 
HDL- C level was observed with eMACEs among pa-
tients with albumin level <4.0 g/dL in the absence of 
inflammation, whereas the association was reversed in 
its presence. Malnutrition interacts with inflammation, 
which can modify the relationship between cholesterol 
and CVD.29 These findings can explain the difference 
in relationship between HDL- C level and adverse out-
comes, depending on the inflammatory status.
The paradoxical association of HDL- C in patients 
with inflammation can be further explained by the 
modified function of HDL in the CKD setting. Reactive 
oxygen species, uremia, and systemic inflammation 
impair the cholesterol uptake capability of HDL.30,31 Its 
capacity of unloading cholesterol is decreased with the 
disturbance of scavenger receptor- B1 by the accumu-
lated oxidation products in renal disease.30,32 Elevated 
HDL- C level owing to the accumulation of malfunction-
ing leftovers does not necessarily indicate improved 
HDL function; rather, it is suggestive of defective re-
verse cholesterol transport. Impaired HDL function 
has been demonstrated ex vivo in patients undergoing 
hemodialysis.33
Our findings may aid in interpreting the Janus- faced 
role of HDL- C. The clinicians performing risk assess-
ment with HDL- C must identify the deleterious factors, 
such as CKD and inflammation, in which the benefi-
cial relationship of HDL- C is uncertain. Several studies 
have reported failure in reducing cardiovascular events 
and/or unexpectedly increasing mortality in subjects 
with intentionally elevated HDL- C levels.34 The par-
ticipants in these studies had previously experienced 
CVD; therefore, they were presumed to have inflamma-
tion, and patients with reduced kidney function were 
also included. In this regard, a customized approach 
is needed for incorporating HDL- C as a factor in car-
diovascular risk stratification in the context of CKD and 
inflammation.
Our study has several limitations. First, because 
this was an observational study, the potential con-
founding factors might not have been thoroughly 
controlled. To minimize the bias, we constructed Cox 
models after rigorous adjustment of several variables 
and used numerous analytical methods. In addition, 
our cohort purely included patients with CKD, with 
≥65% of patients in CKD stage 3 and above, which 
enabled us to examine the relationship between the 
HDL- C level and risk of MACEs in this unique pop-
ulation. Nevertheless, it cannot be overlooked that 
the interpretation of the data is limited because of the 
relatively small size of the cohort, consisting of only 
Korean population with a limited number of events. 
Second, the significant association of HDL- C ≥60 mg/
dL with a lower risk of eMACEs disappeared after 
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the HRs, suggesting this relationship was not strong. 
This finding implies that besides inflammation, other 
factors can affect the relationship between HDL- C 
and CVD in patients with CKD. Third, serum HDL- C 
levels were not measured at the central laboratory. 
However, all participating centers used identical direct 
enzymatic assays for estimating the HDL- C concen-
tration, and all measurements were performed within 
24 hours of sampling. Finally, the qualitative assess-
ment of the composition and function of HDL- C was 
not feasible in this study. As mentioned above, dys-
functional HDL may be more important than HDL- C 
concentration itself. However, although impaired HDL 
function has been proved in patients undergoing dial-
ysis, Bauer et al reported that HDL- C efflux capacity 
cannot predict cardiovascular events in patients with 
CKD.35 Future studies should address this issue on 
the altered composition and function of HDL- C using 
a standardized assay, and be replicated in other eth-
nic populations.
In conclusion, the findings of the present study 
showed that the conventional beneficial association 
of HDL- C was preserved in patients with CKD without 
inflammation, whereas the relationship of HDL- C dif-
fered in its presence. Our hypothesis generated in this 
study should be confirmed in larger sample cohorts 
and requires future research investigating the underly-
ing pathophysiologic mechanisms.
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FH,Mueller M,Horváth T,Doerries C,Heinemann M, et al. Endothelial- 
vasoprotective effects of high- density lipoprotein are impaired in 
patients with type 2 diabetes mellitus but are improved after extended- 
release niacin therapy. Circulation. 2010;121:110– 122. DOI: 10.1161/
CIRCU LATIO NAHA.108.836346.
 24. Riwanto M,Rohrer L,Roschitzki B,Besler C,Mocharla P,Mueller M,Perisa 
D,Heinrich K,Altwegg L,von Eckardstein A, et al. Altered activation of 
endothelial anti- and proapoptotic pathways by high- density lipopro-
tein from patients with coronary artery disease: role of high- density 
lipoprotein- proteome remodeling. Circulation. 2013;127:891– 904. DOI: 
10.1161/CIRCU LATIO NAHA.112.108753.
 25. Himmelfarb J,Stenvinkel P,Ikizler TA,Hakim RM. The elephant in 
uremia: oxidant stress as a unifying concept of cardiovascular dis-
ease in uremia. Kidney Int. 2002;62:1524– 1538. DOI: 10.1046/ 
j.1523- 1755.2002.00600.x.
 26. Gupta J,Mitra N,Kanetsky PA,Devaney J,Wing MR,Reilly M,Shah 
VO,Balakrishnan VS,Guzman NJ,Girndt M, et al. Association between 
albuminuria, kidney function, and inflammatory biomarker profile in 
CKD in CRIC. Clin J Am Soc Nephrol. 2012;7:1938– 1946. DOI: 10.2215/
CJN.03500412.
 27. Corsetti JP,Gansevoort RT,Sparks CE,Dullaart RP. Inflammation re-
duces HDL protection against primary cardiac risk. Eur J Clin Invest. 
2010;40:483– 489. DOI: 10.1111/j.1365- 2362.2010.02287.x.
 28. Corsetti JP,Zareba W,Moss AJ,Rainwater DL,Sparks CE. Elevated HDL is a 
risk factor for recurrent coronary events in a subgroup of non- diabetic postin-
farction patients with hypercholesterolemia and inflammation. Atherosclerosis. 
2006;187:191– 197. DOI: 10.1016/j.ather oscle rosis.2005.09.012.
 29. Contreras G,Hu BO,Astor BC,Greene T,Erlinger T,Kusek JW,Lipkowitz 
M,Lewis JA,Randall OS,Hebert L, et al. Malnutrition- inflammation mod-
ifies the relationship of cholesterol with cardiovascular disease. J Am 
Soc Nephrol. 2010;21:2131– 2142. DOI: 10.1681/ASN.20091 21285.
 30. Reiss AB,Voloshyna I,De Leon J,Miyawaki N,Mattana J. Cholesterol me-
tabolism in CKD. Am J Kidney Dis. 2015;66:1071– 1082. DOI: 10.1053/j.
ajkd.2015.06.028.
 31. Lanktree MB,Thériault S,Walsh M,Paré G. HDL cholesterol, LDL cho-
lesterol, and triglycerides as risk factors for CKD: a Mendelian ran-
domization study. Am J Kidney Dis. 2018;71:166– 172. DOI: 10.1053/j.
ajkd.2017.06.011.
 32. Vaziri ND. HDL abnormalities in nephrotic syndrome and chronic 
kidney disease. Nat Rev Nephrol. 2016;12:37– 47. DOI: 10.1038/
nrneph.2015.180.
 33. Yamamoto S,Yancey PG,Ikizler TA,Jerome WG,Kaseda R,Cox B,Bian 
A,Shintani A,Fogo AB,Linton MF, et al. Dysfunctional high- density li-
poprotein in patients on chronic hemodialysis. J Am Coll Cardiol. 
2012;60:2372– 2379. DOI: 10.1016/j.jacc.2012.09.013.
 34. Schwartz GG,Olsson AG,Abt M,Ballantyne CM,Barter PJ,Brumm 
J,Chaitman BR,Holme IM,Kallend D,Leiter LA, et al. Effects of dalce-
trapib in patients with a recent acute coronary syndrome. N Engl J Med. 
2012;367:2089– 2099. DOI: 10.1056/NEJMo a1206797.
 35. Bauer L,Kern S,Rogacev KS,Emrich IE,Zawada A,Fliser D,Heinemann 
A,Heine GH,Marsche G. HDL cholesterol efflux capacity and cardiovas-
cular events in patients with chronic kidney disease. J Am Coll Cardiol. 
2017;69:246– 247. DOI: 10.1016/j.jacc.2016.10.054.Dow
nloaded from






 http://ahajournals.org by on A
ugust 18, 2021
Appendix. KNOW-CKD Investigators 
Department of Internal Medicine, Seoul National University, Seoul, Korea 
Curie Ahn 
Kook-Hwan Oh 
Soo Kyung Park 
Jayeon Kim 
Dong Wan Chae 
Yun Kyu Oh 
Department of Internal Medicine, The Catholic University of Korea, Seoul 
St. Mary’s Hospital, Seoul, Korea 
Yong-Soo Kim 
Department of Internal Medicine, College of Medicine, Institute of Kidney 
Disease Research, Yonsei University, Seoul, Korea 
Seung Hyeok Han 
Tae-Hyun Yoo 
Kyu Hun Choi 
Department of Internal Medicine, Sungkyunkwan University School of 
Medicine, Kangbuk Samsung Hospital, Seoul, Korea 
Kyu-Beck Lee 
Department of Internal Medicine, Eulji General Hospital, Eulji School of 
Medicine, Seoul, Korea 
Su ah Sung 
Department of Internal Medicine, Chonnam National University Medical 
School, Gwangju, Korea 
Soo Wan Kim 
Department of Internal Medicine, Inje University, Busan Paik Hospital, 
Busan, Korea 
Yeong Hoon Kim 
Sun Woo Kang 
Department of Internal Medicine, Seoul Paik Hospital, College of Medicine, 
Inje University , Seoul, Korea 
Ho Seok Koo 




Department of Prevention and Management, School of Medicine, Inha 





 http://ahajournals.org by on A
ugust 18, 2021
Division of Nephrology, Department of Internal Medicine, National Health 
Insurance Service Medical Center, Ilsan Hospital, Goyang-si, Gyeonggi-do, 
Korea 
Tae-Ik Chang 
Division of Nephrology, Dongtan Sacred Heart Hospital, Hallym University 
Medical Center, Hwaseong-si, Korea 
Ja Ryong Koo 
Department of Internal Medicine, Pusan National University School of 
Medicine, Yangsan, Korea 




 http://ahajournals.org by on A
ugust 18, 2021
Supplemental Methods. Data collection and measurements 
Demographic data, including age, sex, smoking status, alcohol intake, physical activity, 
medical history, and presence of comorbid diseases, were obtained from KNOW-CKD database. 
Based on the smoking status, the participants were classified as never smoked, former smoker, or 
current smoker. Anthropometric data including height and weight were collected at enrollment. Body 
mass index was calculated by dividing initial body weight with height squared (kg/m2). Blood 
pressure was measured in the sitting position after the subject had been in a relaxed state for at least 5 
minutes using an electronic sphygmomanometer. After overnight fasting, blood and urine samples 
were collected and aliquots of the samples were sent to the central laboratory of KNOW-CKD (Lab 
Genomics, Seongnam, Korea) for the estimation of serum creatinine and proteinuria. Other 
biochemical analyses were done at the respective participating centers. The following parameters 
were estimated: complete blood cell count, fasting glucose, blood urea nitrogen, creatinine, albumin, 
calcium, phosphorus, high-sensitivity C-reactive protein, and lipid profile including triglyceride, high-
density lipoprotein cholesterol, and low-density lipoprotein cholesterol. Serum high-sensitivity C-
reactive protein levels were measured at each center using commercially available enzyme-linked 
immunosorbent assay kits. Urine protein-to-creatinine ratio was calculated as urine protein 





 http://ahajournals.org by on A
ugust 18, 2021













Primary kidney disease <0.001 
DMN 184 (35.8%) 148 (27.6%) 61 (15.0%) 69 (17.0%) 462 (24.8%) 
Hypertensive 119 (23.2%) 122 (22.7%) 75 (18.4%) 53 (13.1%) 369 (19.8%) 
Glomerulonephritis 122 (23.7%) 163 (30.4%) 143 (35.1%) 151 (37.2%) 579 (31.1%) 
PKD 51 (9.9%) 65 (12.1%) 96 (23.6%) 111 (27.3%) 323 (17.3%) 
Others 38 (7.4%) 39 (7.3%) 32 (7.9%) 22 (5.4%) 131 (7.0%) 
Comorbidities 
PVD 26 (5.1%) 18 (3.4%) 18 (4.4%) 11 (2.7%) 73 (3.9%) 0.25 
CHF 12 (2.3%) 8 (1.5%) 6 (1.5%) 2 (0.5%) 28 (1.5%) 0.16 
Laboratory parameters 
Phosphate (mg/dL) 3.7 ± 0.7 3.7 ± 0.7 3.6 ± 0.6 3.8 ± 0.7 3.7 ± 0.7 0.02 
PTH (pg/mL) 60.0 (36.9-106.4) 50.9 (33.2-78.6) 48.4 (31.9-76.4) 48.1 (32.3-77.1) 51.2 (33.3-83.7) <0.001 
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Table S2. Statistical adjustments for multiple comparisons 
HDL-C category 
<40 mg/dL 40-49 mg/dL 50-59 mg/dL ≥60 mg/dL 
HR [95% CI] P* HR [95% CI] P* HR [95% CI] P* HR [95% CI] P* 
All 
vs. <40 mg/dL - 1.08 [0.59-1.97] 1.00 1.13 [0.57-2.25] 1.00 0.77 [0.35-1.73] 1.00 
vs. 40-49 mg/dL - 1.05 [0.55-1.98] 1.00 0.72 [0.34-1.50] 1.00 
vs. 50-59 mg/dL - 0.68 [0.32-1.48] 1.00 
vs. ≥60 mg/dL - 
In the absence of inflammation 
vs. <40 mg/dL - 0.91 [0.41-2.04] 1.00 0.87 [0.33-2.26] 1.00 0.38 [0.12-1.26] 0.20 
vs. 40-49 mg/dL - 0.95 [0.40-2.28] 1.00 0.42 [0.14-1.25] 0.22 
vs. 50-59 mg/dL - 0.44 [0.15-1.35] 0.32 
vs. ≥60 mg/dL - 
In the presence of inflammation 
vs. <40 mg/dL - 1.38 [0.55-3.43] 0.93 1.71 [0.61-4.80] 1.00 2.16 [0.68-6.79] 0.47 
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vs. 50-59 mg/dL - 1.26 [0.41-3.90] 1.00 
vs. ≥60 mg/dL - 
Cox proportional-hazards model was constructed to evaluate the associations between serum HDL-C category and eMACE based on the 
presence of inflammation. The model is adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, 
systolic blood pressure, presence of coronary artery disease, diabetes, laboratory parameters including fasting blood glucose, low-density 
lipoprotein cholesterol, triglycerides, serum albumin, high-sensitivity C-reactive protein, estimated glomerular filtration rate, urine protein-to-
creatinine ratio, and medications’ use including renin-angiotensin system blockers, diuretics, and statins. 
* Corrected using Bonferroni’s method due to multiple testing.
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Table S3. Hazard ratios for the eMACE outcomes based on the HDL-C categories stratified into quartiles overall and in the absence 
and presence of inflammation 
HDL-C quartiles 
Q1 Q2 Q3 Q4 
HR [95% CI] P HR [95% CI] P HR [95% CI] P HR [95% CI] P 
All 
Model 1 1.02 [0.64-1.62] 0.93 Reference 1.18 [0.74-1.88] 0.49 0.86 [0.51-1.44] 0.56 
Model 2 1.16 [0.71-1.90] 0.54 Reference 1.23 [0.77-1.99] 0.39 0.82 [0.48-1.42] 0.48 
Model 3 1.15 [0.70-1.87] 0.59 Reference 1.26 [0.78-2.03] 0.35 0.83 [0.48-1.43] 0.50 
In the absence of inflammation 
Model 1 0.86 [0.49-1.53] 0.61 Reference 0.73 [0.39-1.37] 0.33 0.37 [0.17-0.84] 0.02 
Model 2 0.96 [0.53-1.74] 0.89 Reference 0.72 [0.38-1.37] 0.32 0.37 [0.16-0.85] 0.02 
Model 3 0.98 [0.54-1.78] 0.95 Reference 0.76 [0.39-1.46] 0.41 0.37 [0.16-0.85] 0.02 
In the presence of inflammation 
Model 1 0.90 [0.44-1.85] 0.77 Reference 0.88 [0.44-1.79] 0.73 1.28 [0.66-2.48] 0.47 
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Model 3 0.97 [0.46-2.06] 0.93 Reference 0.99 [0.48-2.05] 0.98 1.28 [0.62-2.63] 0.51 
Model 1: adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, systolic blood pressure, presence 
of coronary artery disease, and diabetes 
Model 2: Model 1 + laboratory parameters including fasting blood glucose, low-density lipoprotein cholesterol, triglyceride, serum albumin, 
high-sensitivity C-reactive protein, estimated glomerular filtration rate, and urine protein-to-creatinine ratio  
Model 3: Model 2 + medications’ use including renin-angiotensin system blockers, diuretics, and statins 
CI, confidence interval; eMACE, extended major adverse cardiovascular events; HDL-C, high-density lipoprotein cholesterol; HR, hazard 
ratio; SD, standard deviation D
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Table S4. Hazard ratios for the eMACE outcomes based on the HDL-C categories using a different hsCRP cutoff value for the status 
of inflammation 
HDL-C category 
<40 mg/dL 40-49 mg/dL 50-59 mg/dL ≥60 mg/dL 
HR [95% CI] P HR [95% CI] P HR [95% CI] P HR [95% CI] P 
In the absence of inflammation 
Model 1 0.62 [0.28-1.36] 0.24 Reference 0.64 [0.29-1.41] 0.27 0.34 [0.13-0.88] 0.03 
Model 2 0.65 [0.29-1.49] 0.31 Reference 0.59 [0.26-1.36] 0.22 0.38 [0.14-1.01] 0.05 
Model 3 0.63 [0.27-1.45] 0.27 Reference 0.60 [0.26-1.39] 0.23 0.36 [0.14-0.95] 0.04 
In the presence of inflammation 
Model 1 1.00 [0.60-1.67] 1.00 Reference 1.30 [0.73-2.33] 0.37 1.26 [0.65-2.43] 0.49 
Model 2 0.97 [0.57-1.67] 0.93 Reference 1.29 [0.71-2.34] 0.40 1.15 [0.58-2.27] 0.69 
Model 3 0.98 [0.57-1.68] 0.94 Reference 1.33 [0.73-2.42] 0.35 1.18 [0.60-2.33] 0.63 
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Model 1: adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, systolic blood pressure, presence 
of coronary artery disease, and diabetes 
Model 2: Model 1 + laboratory parameters including fasting blood glucose, low-density lipoprotein cholesterol, triglyceride, serum albumin, 
high-sensitivity C-reactive protein, estimated glomerular filtration rate, and urine protein-to-creatinine ratio  
Model 3: Model 2 + medications’ use including renin-angiotensin system blockers, diuretics, and statins 
CI, confidence interval; eMACE, extended major adverse cardiovascular events; HDL-C, high-density lipoprotein cholesterol; HR, hazard 
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Table S5. Time-varying model for risk of eMACE with lipid-lowering drugs treated as a time-varying covariate 
HDL-C per SD 
HDL-C category 
<40 mg/dL 40-49 mg/dL 50-59 mg/dL ≥60 mg/dL 
HR [95% CI] P HR [95% CI] P HR [95% CI] P HR [95% CI] P HR [95% CI] P 
All 
Model 1 0.83 [0.67-1.05] 0.13 0.89 [0.56-1.40] 0.61 Reference 0.91 [0.54-1.52] 0.72 0.61 [0.33-1.13] 0.12 
Model 2 0.80 [0.95-1.03] 0.09 0.90 [0.56-1.46] 0.68 Reference 0.91 [0.54-1.53] 0.71 0.59 [0.31-1.12] 0.11 
Model 3 0.81 [0.63-1.04] 0.10 0.89 [0.55-1.43] 0.62 Reference 0.92 [0.54-1.55] 0.75 0.59 [0.31-1.11] 0.10 
In the absence of inflammation 
Model 1 0.71 [0.52-0.98] 0.04 0.91 [0.47-1.75] 0.78 Reference 1.00 [0.50-2.02] 1.00 0.36 [0.14-0.94] 0.04 
Model 2 0.65 [0.45-0.93] 0.02 1.01 [0.51-2.01] 0.97 Reference 0.96 [0.47-1.99] 0.92 0.35 [0.13-0.93] 0.04 
Model 3 0.65 [0.45-0.94] 0.02 1.04 [0.52-2.06] 0.91 Reference 1.01 [0.49-2.10] 0.98 0.36 [0.13-0.96] 0.04 
In the presence of inflammation 
Model 1 1.10 [0.81-1.51] 0.54 0.81 [0.42-1.55] 0.52 Reference 0.88 [0.41-1.91] 0.75 1.36 [0.59-3.11] 0.47 
Model 2 1.13 [0.82-1.56] 0.47 0.69 [0.34-1.37] 0.29 Reference 0.85 [0.38-1.93] 0.70 1.37 [0.58-3.27] 0.48 
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Model 1: adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, systolic blood pressure, presence 
of coronary artery disease, diabetes, and medication use of statin 
Model 2: Model 1 + laboratory parameters including fasting blood glucose, low-density lipoprotein cholesterol, triglyceride, serum albumin, 
high-sensitivity C-reactive protein, estimated glomerular filtration rate, and urine protein-to-creatinine ratio  
Model 3: Model 2 + medications’ use including renin-angiotensin system blockers, and diuretics 
CI, confidence interval; eMACE, extended major adverse cardiovascular events; HDL-C, high-density lipoprotein cholesterol; HR, hazard 
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Table S6. Hazard ratios for non-fatal MACE based on the HDL-C levels in the absence and presence of inflammation 
HDL-C per SD 
HDL-C category 
<40 mg/dL 40-49 mg/dL 50-59 mg/dL ≥60 mg/dL 
HR [95% CI] P HR [95% CI] P HR [95% CI] P HR [95% CI] P HR [95% CI] P 
All 
Model 1 0.88 [0.71-1.09] 0.23 0.96 [0.61-1.51] 0.87 Reference 1.11 [0.67-1.82] 0.69 0.75 [0.42-1.34] 0.34 
Model 2 0.83 [0.45-1.30] 0.11 1.01 [0.63-1.63] 0.97 Reference 1.12 [0.67-1.83] 0.68 0.70 [0.39-1.27] 0.24 
Model 3 0.84 [0.67-1.06] 0.15 0.98 [0.61-1.58] 0.94 Reference 1.13 [0.69-1.87] 0.63 0.70 [0.39-1.28] 0.25 
In the absence of inflammation 
Model 1 0.74 [0.55-0.99] 0.04 0.98 [0.53-1.80] 0.95 Reference 0.92 [0.48-1.78] 0.81 0.43 [0.19-1.00] 0.05 
Model 2 0.67 [0.48-0.94] 0.02 1.09 [0.58-2.05] 0.79 Reference 0.87 [0.44-1.71] 0.68 0.42 [0.18-0.98] 0.04 
Model 3 0.67 [0.48-0.94] 0.02 1.09 [0.58-2.06] 0.79 Reference 0.89 [0.45-1.78] 0.75 0.41 [0.17-0.97] 0.04 
In the presence of inflammation 
Model 1 1.17 [0.87-1.57] 0.30 0.93 [0.47-1.88] 0.85 Reference 1.43 [0.67-3.08] 0.36 1.70 [0.74-3.90] 0.21 
Model 2 1.12 [0.82-1.53] 0.47 0.84 [0.40-1.74] 0.63 Reference 1.47 [0.67-3.20] 0.34 1.54 [0.64-3.70] 0.33 
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Model 1: adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, systolic blood pressure, presence of coronary 
artery disease, and diabetes 
Model 2: Model 1 + laboratory parameters including fasting blood glucose, low-density lipoprotein cholesterol, triglycerides, serum albumin, high-
sensitivity C-reactive protein, estimated glomerular filtration rate, and urine protein-to-creatinine ratio  
Model 3: Model 2 + medications’ use including renin-angiotensin system blockers, diuretics, and statins 
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Table S7. Hazard ratios for all-cause mortality based on the HDL-C levels in the absence and presence of inflammation 
HDL-C per SD 
HDL-C category 
<40 mg/dL 40-49 mg/dL 50-59 mg/dL ≥60 mg/dL 
HR [95% CI] P HR [95% CI] P HR [95% CI] P HR [95% CI] P HR [95% CI] P 
All 
Model 1 0.91 [0.72-1.16] 0.44 1.35 [0.80-2.26] 0.26 Reference 1.13 [0.62-2.06] 0.70 0.88 [0.46-1.71] 0.71 
Model 2 0.99 [0.77-1.26] 0.91 1.24 [0.72-2.16] 0.44 Reference 1.12 [0.60-2.09] 0.73 0.93 [0.47-1.81] 0.82 
Model 3 1.01 [0.79-1.29] 0.95 1.18 [0.68-2.05] 0.57 Reference 1.16 [0.62-2.16] 0.65 0.92 [0.47-1.80] 0.82 
In the absence of inflammation 
Model 1 0.79 [0.56-1.13] 0.20 1.56 [0.73-3.36] 0.25 Reference 1.08 [0.44-2.66] 0.87 0.67 [0.24-1.82] 0.43 
Model 2 0.81 [0.54-1.22] 0.32 1.81 [0.78-4.20] 0.16 Reference 1.17 [0.47-2.93] 0.74 0.75 [0.27-2.07] 0.58 
Model 3 0.81 [0.54-1.22] 0.32 1.64 [0.70-3.88] 0.26 Reference 1.16 [0.45-3.00] 0.75 0.69 [0.25-1.94] 0.48 
In the presence of inflammation 
Model 1 1.12 [0.82-1.53] 0.46 1.02 [0.50-2.07] 0.97 Reference 1.12 [0.49-2.56] 0.78 1.18 [0.49-2.87] 0.71 
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Model 3 1.26 [0.93-1.71] 0.13 0.70 [0.33-1.48] 0.35 Reference 0.99 [0.41-2.37] 0.98 1.20 [0.48-2.99] 0.70 
Model 1: adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, systolic blood pressure, presence of coronary 
artery disease, and diabetes 
Model 2: Model 1 + laboratory parameters including fasting blood glucose, low-density lipoprotein cholesterol, triglycerides, serum albumin, high-sensitivity 
C-reactive protein, estimated glomerular filtration rate, and urine protein-to-creatinine ratio  
Model 3: Model 2 + medications’ use including renin-angiotensin system blockers, diuretics, and statins 
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Figure S1. Flow diagram of study participants 
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Figure S2. Histogram and kernel density plot showing the distribution of HDL-C 
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A significant inverse relationship was observed between the HDL-C level and hsCRP level. Linear regression analysis was performed with a 
curvilinear approach to determine the relationship between the variables. 
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Figure S4. Restricted cubic spline curves for the association between the HDL-C level and the risk of eMACE (A) regardless of 
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Restricted cubic spline curves for the adjusted hazard ratios show opposite trend for the relationship between HDL-C levels and risk of eMACE in 
patients with and without inflammation. The model is adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational 
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cholesterol, triglycerides, serum albumin, high-sensitivity C-reactive protein, estimated glomerular filtration rate, urine protein-to-creatinine ratio, and 
medications’ use including renin-angiotensin system blockers, diuretics, and statins. 
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Figure S5. Association of the baseline serum HDL-C level with non-fatal cardiovascular disease 
Overall, HDL-C level was not associated with the risk of non-fatal MACE; however, an inverse association was observed in patients without 
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The model is adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, systolic blood pressure, presence of 
coronary artery disease, diabetes, laboratory parameters including fasting blood glucose, low-density lipoprotein cholesterol, triglycerides, serum albumin, 
high-sensitivity C-reactive protein, estimated glomerular filtration rate, urine protein-to-creatinine ratio, and medications’ use including renin-angiotensin 
system blockers, diuretics, and statins. 
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Figure S6. Association of the baseline serum HDL-C level with all-cause mortality 
In the analysis for mortality, adjusted HRs were lower in patients without inflammation and with higher HDL-C levels compared to the reference 
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The model is adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, systolic blood pressure, presence of 
coronary artery disease, diabetes, laboratory parameters including fasting blood glucose, low-density lipoprotein cholesterol, triglycerides, serum albumin, 
high-sensitivity C-reactive protein, estimated glomerular filtration rate, urine protein-to-creatinine ratio, and medications’ use including renin-angiotensin 
system blockers, diuretics, and statins. 
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Figure S7. Cumulative incidence curves for non-fatal cardiovascular disease based on the HDL-C categories (A) regardless of 
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Figure S8. Kaplan-Meier curves for the cumulative incidence of all-cause mortality based on the HDL-C categories (A) regardless of 
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Figure S9. Forest plot for subgroup analysis 





Overall 1,864 140 (7.5) 0.85 [0.68-1.06] 
Absent 1,142 76 (6.7) 0.67 [0.48-0.92] 
0.003 
Present 722 64 (8.9) 1.19 [0.90-1.57] 
Age 
Absent 
< 60 years 763 27 (3.5) 0.63 [0.35-1.12] 
0.76 
≥ 60 years 379 49 (12.9) 0.68 [0.46-1.02] 
Present 
< 60 years 448 29 (6.5) 1.26 [0.81-1.96] 
0.38 
≥ 60 years 274 35 (12.8) 0.98 [0.61-1.60] 
Sex 
Absent 
Male 678 50 (7.4) 0.71 [0.47-1.07] 
0.14 
Female 464 26 (5.6) 0.54 [0.30-0.96] 
Present 
Male 455 48 (10.5) 1.48 [0.99-2.22] 
0.40 
Female 267 16 (6.0) 1.05 [0.60-1.85] 
BMI 
Absent 
< 25 kg/m2 735 41 (5.6) 0.74 [0.48-1.14] 
0.52 
≥ 25 kg/m2 407 35 (8.6) 0.58 [0.34-0.96] 
Present 
< 25 kg/m2 351 43 (12.3) 1.41 [0.94-2.10] 
0.95 
≥ 25 kg/m2 371 21 (5.7) 1.07 [0.61-1.89] 
DM 
Absent 
Present 355 43 (12.1) 0.87 [0.58-1.29] 
0.30 
Absent 785 33 (4.2) 0.42 [0.24-0.76] 
Present 
Present 267 29 (10.9) 1.39 [0.88-2.21] 
0.73 
Absent 452 34 (7.5) 0.99 [0.62-1.56] 
SBP 
Absent 
< 130 mmHg 695 39 (5.6) 0.70 [0.45-1.08] 
0.61 
≥ 130 mmHg 447 37 (8.3) 0.69 [0.43-1.11] 
Present 
< 130 mmHg 385 37 (9.6) 1.07 [0.74-1.53] 
0.85 
≥ 130 mmHg 337 27 (8.0) 1.15 [0.67-1.99] 
eGFR 
Absent 
≥ 50 ml/min/1.73m2 557 22 (3.9) 0.25 [0.11-0.55] 
0.30 
< 50 ml/min/1.73m2 585 54 (9.2) 0.77 [0.53-1.14] 
Present 
≥ 50 ml/min/1.73m2 300 24 (8.0) 1.28 [0.78-2.11] 
0.40 




≥ 4.0 g/dL 912 61 (6.7) 0.73 [0.52-1.05] 
0.17 
< 4.0 g/dL 230 15 (6.5) 0.32 [0.10-1.00] 
Present 
≥ 4.0 g/dL 542 46 (8.5) 0.91 [0.62-1.34] 
0.02 
< 4.0 g/dL 180 18 (10.0) 2.38 [1.19-4.77] 
UPCR 
Absent 
< 1.0 g/g 777 50 (6.4) 0.70 [0.47-1.02] 
1.00 
≥ 1.0 g/g 365 26 (7.1) 0.55 [0.30-1.01] 
Present 
< 1.0 g/g 473 39 (8.2) 1.01 [0.70-1.45] 
0.52 
≥ 1.0 g/g 249 25 (10.0) 1.30 [0.71-2.38] 
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The risk modifying effect of inflammation on the relationship between HDL-C level and risk of eMACE existed among most subgroups. Significant 
interaction was observed between serum albumin level and HDL-C level for eMACE depending on the inflammatory status. Hazard ratios with 95% 
confidence interval error bars are presented.  
The model is adjusted for age, sex, body mass index, smoking status, socioeconomic status, educational status, systolic blood pressure, presence of 
coronary artery disease and diabetes, laboratory parameters including fasting blood glucose, low-density lipoprotein cholesterol, triglycerides, serum 
albumin, high-sensitivity C-reactive protein, estimated glomerular filtration rate, urine protein-to-creatinine ratio, and medications’ use including renin-
angiotensin system blockers, diuretics, and statins. 
BMI, body mass index; CI, confidence interval; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; uPCR, 
urine protein-to-creatinine ratio Dow
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